Cargando…
Quantifying cell death induced by doxorubicin, hyperthermia or HIFU ablation with flow cytometry
Triggered release and targeted drug delivery of potent anti-cancer agents using hyperthermia-mediated focused-ultrasound (FUS) is gaining momentum in the clinical setting. In early phase studies, tissue biopsy samples may be harvested to assess drug delivery efficacy and demonstrate lack of instanta...
Autores principales: | Lyon, Paul Christopher, Suomi, Visa, Jakeman, Philip, Campo, Leticia, Coussios, Constantin, Carlisle, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7902827/ https://www.ncbi.nlm.nih.gov/pubmed/33623089 http://dx.doi.org/10.1038/s41598-021-83845-2 |
Ejemplares similares
-
Multi-focal HIFU reduces cavitation in mild-hyperthermia
por: Chaplin, Vandiver, et al.
Publicado: (2017) -
MRgHIFU – experimental perivascular volumetric ablation in the liver
por: Carling, Ulrik, et al.
Publicado: (2015) -
Clinical trial protocol for PanDox: a phase I study of targeted chemotherapy delivery to non-resectable primary pancreatic tumours using thermosensitive liposomal doxorubicin (ThermoDox®) and focused ultrasound
por: Spiers, Laura, et al.
Publicado: (2023) -
Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial
por: Lyon, Paul C, et al.
Publicado: (2018) -
Clinical trial protocol for TARDOX: a phase I study to investigate the feasibility of targeted release of lyso-thermosensitive liposomal doxorubicin (ThermoDox®) using focused ultrasound in patients with liver tumours
por: Lyon, Paul C., et al.
Publicado: (2017)